维普中文期刊产品整合服务
6篇 您的检索式:作者名="Komajda M."
    题名 作者 年代 出处 被引量
1新发贫血对慢性心力衰竭发病率和死亡率的影响:来自COMET研究的结果显示文摘Aims: Anaemia is a common comorbidity in chronic heart failure(CHF). The predictors of new onset anaemia(NOA) and its long-term prognostic value, particularly in patients treated with beta-blockers, are not known. Methods and results: In COMET, 3029 patients with CHF in NYHA Ⅱ-IV and EF< 35%were randomized to carvedilol or metoprolol tartrate and were followed for an average of 58 months. Plasma haemoglobin(Hb) concentrations were measured at a central laboratory at randomization, at four monthly intervals for the first year and annually thereafter. According to WHO criteria, anaemia was defined when Hb measured< 13 g/dL for men and< 12 g/dL for women. We considered anaemia to be severe when Hb< 11.5 g/dL for men and< 10.5 g/dL for women. The baseline mean Hb was 14.2±1.5 g/dL(n=2996) and 15.9%of patients had anaemia(males, 16.0%; females, 15.2%). At baseline, severe anaemia was found in 3.3%of patients(males, 3.6%; females, 2.0%). During the study, all-cause mortality(RR 1.47) death or hospitalization(RR 1.28), and heart failure hospitalization(RR 1.43, all P< 0.0001) were higher in anaemic when compared with non-anaemic patients. In patients without anaemia at baseline, at the end of the study, the cumulative frequency of NOA was 28.1%in males and 27.0%in females. NOA increased over time from 14.2%at year 1 to 27.5%at year 5. Predictors of NOA were: higher age, diuretic dose, creatinine(all P< 0.0001), higher serum potassium, lower serum sodium, body mass index, and use of aldosterone antagonists, carvedilol, and digitalis(all P< 0.03). Treatment with carvedilol(vs. metoprolol tartrate) was associated with a 24%increased risk to develop NOA(P=0.0047),but not severe anaemia(P=0.18). Patients with a Hb decrease of >3 g/dL(RR 3.37, P< 0.0001) or of 2.0-3.0 g/dL(RR 1.47, P=0.011) from baseline had an increased subsequent mortality when compared with patients having Hb increases of 0-1.0 g/dL. Conclusion: In stable ambulatory CHF patients, development of NOA is frequent and can be predicted by a set of clinical variables. Decreases in Hb over time relate to future increased morbidity and mortality.Komajda M. Anker S.D. Charlesworth A. 郭俊 2006世界核心医学期刊文摘(心脏病学分册)2006,,12:14
2Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve)显示文摘Michael B?hm Ana‐Cristina Perez Pardeep S. Jhund Jan C. Reil Michel Komajda Michael R. Zile Robert S McKelvie Inder S Anand Barry M. Massie Peter E. Carson John J. V. McMurray 2014Eur J Heart Fail2014,,7:1
3Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis?显示文摘Dan Rusinaru Christophe Tribouilloy Colin Berry A. Mark Richards Gillian A. Whalley Nikki Earle Katrina K. Poppe Marco Guazzi Stella M. Macin Michel Komajda Robert N. Doughty 2012European Journal of Heart Failure2012,,10:1
4Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis?显示文摘Dan Rusinaru Christophe Tribouilloy Colin Berry A. Mark Richards Gillian A. Whalley Nikki Earle Katrina K. Poppe Marco Guazzi Stella M. Macin Michel Komajda Robert N. Doughty 2012European Journal of Heart Failure2012,,10:1
5Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)显示文摘Adrian F. Hernandez Christopher M. O’Connor Randall C. Starling Craig J. Reist Paul W. Armstrong Kenneth Dickstein Todd J. Lorenz W. Brian Gibler Vic Hasselblad Michel Komajda Barry Massie John J.V. McMurray Markku Nieminen Jean L. Rouleau Karl Swedberg R 2009American Heart Journal2009,,2:1
6Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial显示文摘Michael R. Zile William H. Gaasch Inder S. Anand Markus Haass William C. Little Alan B. Miller Jose Lopez-Sendon John R. Teerlink Michel White John J. McMurray Michel Komajda Robert McKelvie Agata Ptaszynska Scott J. Hetzel Barry M. Massie Peter E. Carson 2010Circulation2010,,12:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费